Suppr超能文献

脐带间充质干细胞来源的细胞外囊泡的制备及鉴定用于临床检测。

Manufacturing and characterization of extracellular vesicles from umbilical cord-derived mesenchymal stromal cells for clinical testing.

机构信息

GMP Laboratory, Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University (PMU), Salzburg, Austria; Department of Transfusion Medicine, Paracelsus Medical University (PMU), Salzburg, Austria; Celericon Therapeutics G.m.b.H., Paracelsus Medical University (PMU), Salzburg, Austria.

GMP Laboratory, Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University (PMU), Salzburg, Austria; Department of Transfusion Medicine, Paracelsus Medical University (PMU), Salzburg, Austria; Research Program Nanovesicular Therapies, Paracelsus Medical University (PMU), Salzburg, Austria.

出版信息

Cytotherapy. 2019 Jun;21(6):581-592. doi: 10.1016/j.jcyt.2018.12.006. Epub 2019 Apr 9.

Abstract

Extracellular vesicles (EVs) derived from mesenchymal stromal cells (MSCs) may deliver therapeutic effects that are comparable to their parental cells. MSC-EVs are promising agents for the treatment of a variety of diseases. To reach the intermediate goal of clinically testing safety and efficacy of EVs, strategies should strive for efficient translation of current EV research. On the basis of our in vitro an in vivo findings regarding the biological actions of EVs and our experience in manufacturing biological stem cell therapeutics for routine use and clinical testing, we discuss strategies of manufacturing and quality control of umbilical cord-derived MSC-EVs. We introduce guidelines of good manufacturing practice and their practicability along the path from the laboratory to the patient. We present aspects of manufacturing and final product quality testing and highlight the principle of "The process is the product." The approach presented in this perspective article may facilitate translational research during the development of complex biological EV-based therapeutics in a very early stage of manufacturing as well as during early clinical safety and proof-of-concept testing.

摘要

外泌体(EVs)来源于间充质基质细胞(MSCs),可能具有与其亲本细胞相当的治疗效果。MSC-EVs 是治疗多种疾病的有前途的药物。为了达到临床测试 EVs 的安全性和有效性的中期目标,策略应努力实现当前 EV 研究的高效转化。基于我们关于 EV 生物学作用的体外和体内发现,以及我们在制造常规使用和临床测试的生物干细胞治疗方面的经验,我们讨论了制造和质量控制脐带间充质干细胞衍生 EVs 的策略。我们介绍了良好生产规范的指南及其在从实验室到患者的路径中的实用性。我们介绍了制造和最终产品质量测试的各个方面,并强调了“过程即产品”的原则。本文提出的方法可以促进复杂生物 EV 治疗药物在制造的早期阶段以及早期临床安全性和概念验证测试期间的转化研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验